GlassScriptPhysician profile
Trey Michel Haugen
NPI 1548740772
$975.63
in general payments reported to CMS, 2019-2025
15 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.95 · 2022: $229 · 2023: $348 · 2024: $238 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $214.17 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $161.31 | 2022-2025 | Cequa |
| Rxsight INC | $124.80 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Novartis Pharmaceuticals Corporation | $93.20 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $69.06 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $68.31 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $53.61 | 2025 | Xdemvy |
| Alcon Vision LLC | $39.93 | 2023-2024 | Rocklatan, Precision 1 |
| Dompe US, INC. | $32.15 | 2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $29.62 | 2025 | Eylea Hd, Eylea |
| Kala Pharmaceuticals, INC. | $23.22 | 2022 | |
| Omeros Corporation | $20.95 | 2021 | |
| Thea Pharma INC. | $19.58 | 2023 | |
| Horizon Therapeutics Plc | $12.97 | 2023 | Tepezza |
| Oasis Medical, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trey Haugen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.